Active pharmaceutical ingredient manufacturers, CDMO players, and intermediates suppliers in India's pharma supply chain.
Sectors represented: Healthcare, Consumer Services
Increased propensity to outsource manufacturing of intermediates & APIs. ◼Enables asset light model and ability to focus on development of novel products for venture. capital backed start-ups. ◼Provides cost advantages and supply chain efficiencies g of intermediates & APIs. ◼Enables asset light model and ability to focus on development of novel products for venture. capital backed start-ups.
Unichem in its journey of several decades, also have the privilege to partner. with renowned pharmaceutical companies in offering third-party manufacturing services a comprehensive range of pharmaceutical. products tailored to the specific requirements of its clients. This association stands as a testament to its reliability, trustworthiness and. commitment to delivering excellence.
Manufacturer from India. ➢Our Business Model. ➢Our Key Products and their Application. ➢Our Products. ➢Capex. ➢Our strategy and outlook. ➢Industry Overview. Advanced Pharma intermediate vanced Intermediate. Manufacturer from India. ➢Our Business Model. ➢Our Key Products and their Application. ➢Our Products. ➢Capex. ➢Our strategy and outlook. ➢Industry Overview. Advanced Pharma intermediate.
Alignmentofinterestofallinternal. stakeholders. Long-standing Relationships. Longstandingrelationshipswith. suppliersandcustomers-Cost-efficient,. consistent,sustainablerawmaterial. supplyandrevenue. Cost Leadership. Fromprocurementtoproductiontillsales Long-standing Relationships. Longstandingrelationshipswith. suppliersandcustomers-Cost-efficient,. consistent,sustainablerawmaterial.
Although the CDMO API market is dominated by small. molecules, higher growth is expected in the segments of high-. potency APIs and large molecules. The industry is increasing. backward integration to mitigate the pricing pressure. small. molecules, higher growth is expected in the segments of high-. potency APIs and large molecules. The industry is increasing.
Market Opportunity. 22. Pharmaceutical Supply Chain in India is Highly Fragmented. Companies ~3,000. Man. business, business. development, supply chain management, and business. operation in our Company. Market Opportunity. 22. Pharmaceutical Supply Chain in India is Highly Fragmented. Companies ~3,000. Man. Units 10,500. ~3,000 – 5,000. ~65,000. ~900,000. 40 – 60%. 2 – 4%. 8 – 15%.
Initially, upfront, you receive licensing, and then as the sales pick up, there will be profits, and. the margin profile can improve for themselves, like, depending on if the product kind of. continues on its sales trajectory and all, especially with your own ANDA, like, you what you. sell. Deval Shah: Again, from the product mix, it is a continuous process. ng on if the product kind of.
Small Molecule Pipeline Stays Robust, remains the. majority of FDA Approvals and Clinical Phase Pipeline. A. Small Molecule Pipeline continues to grow. despite growth in Biologics. Small Molecule Approvals remain. the majority. Source: Informa – Citeline Clinical Intelligence. 65%. 71%. 79%. 63%. 72%. 59%. 69%. 35%. 29%. 21%. 37% lecule Pipeline continues to grow. despite growth in Biologics.